FDA’s Woodcock Cautions Against Trying To “Legislate A New Generation Of Biomarkers”
This article was originally published in RPM Report
New approaches to biomarker qualification are big part of industry’s agenda for “21st Century Cures,” but CDER Director Janet Woodcock remains concerned about efforts to legislate ahead of the science.
You may also be interested in...
There may be significant savings from eliminating wasteful packaging for high cost specialty drugs. The US FDA, however, is urging policy makers not to overlook the importance of patient safety in packaging issues.
CMS streamlined process for enhanced payments is having an impact: seven antibiotic applications for New Technology Add-On Payment status in 2021—including one for a product that has been marketed for more than five years.
Updated guidance on its authority to mandate postmarketing studies affirms that a new power to impose requirements to look for diminished efficacy reaches beyond the opioid drug class.